Precision ADM Inc reported on Thursday the receipt of the ISO 13485:2016 Quality Management System certification for its first Canadian metal Additive and Subtractive manufacturing services company.
This ISO 13485:2016 industry standard reportedly represents the comprehensive set of requirements for the design and manufacture of medical devices.
Achieving ISO 13485 Registration and Certification allows the company to manufacture medical devices, including Orthopaedic Implants, using the latest digital manufacturing technologies that can lower production costs by reducing waste and decreasing time to market by simplifying - or eliminating - tooling and equipment.
The Additive Manufacturing makes it possible to produce custom, patient-specific designs and devices with complex geometries, with potential lower cost than traditional manufacturing methods. The company is currently targeting additively manufactured medical devices produced in Titanium, Cobalt-Chrome and stainless-steel alloys.
Headquartered in Winnipeg, Manitoba, Canada, Precision ADM Inc is an engineering and manufacturing solutions provider that uses Additive Manufacturing, also known as 3D Printing, as a core technology, complimented by multi-axis machining to manufacture high value components and devices for the medical and industrial sectors.
BioCryst wins FDA approval for oral HAE prophylaxis in young children
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system
Bonesupport shifts CERAMENT V review to FDA's De Novo pathway
Neola Medical secures US patent for disposable lung monitoring probes
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance
Aetna to launch generative AI-powered conversational experience
Maxx Orthopedics Receives FDA 510(k) Clearance for Its Libertas® Bipolar Hip System
Ascletis Pharma announces ASC36 and ASC35 co-formulation for clinical development
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies
Nurami Medical completes Phase 1 milestones in EIC-backed grant for Artifix
Organon to sell JADA System to Laborie for up to USD465m
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities